Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease.

Related Articles Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 May 22;: Authors: Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D’Haens G, Vermeire S, Gils A Abstract BACKGROUND AND AIMS: In the TAILORIX trial, no benefit could be shown of infliximab dose escalation based on pharmacokinetic (infliximab serum concentrations) and pharmacodynamic (biomarkers and symptoms) monitoring compared to dose escalation based…

Read More

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis in real-life.

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis in real-life. Aliment Pharmacol Ther. 2019 May 22;: Authors: Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A Abstract BACKGROUND: CT-P13, a biosimilar of the reference product infliximab, has been approved for the treatment of ulcerative colitis on the basis of the results of trials conducted in patients with spondyloarthritis and rheumatoid arthritis. AIM: To compare the effectiveness and safety of CT-P13 and the reference product in infliximab-naive patients with ulcerative…

Read More

Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials.

Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials. Clin Gastroenterol Hepatol. 2019 May 17;: Authors: Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V Abstract BACKGROUND & AIMS: With several options available for patients with moderate-severe ulcerative colitis (UC), rapidity of symptom resolution could be an important differentiator. We compared the efficacy and speed of onset of action of infliximab vs golimumab induction therapy using patient-level data from phase 3 trials…

Read More

Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn’s disease.

Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn’s disease. J Gastroenterol Hepatol. 2019 Apr 30;: Authors: Park SH, Hong M, Lee HS, Ye BD, Hwang SW, Jung S, Baek J, Moon J, Kim BM, Oh SH, Kim KM, Lee I, Im CN, Liu J, McGovern DPB, Yang SK, Song K Abstract BACKGROUND AND AIM: Anti-tumour necrosis factor (TNF) agents, such as infliximab (IFX), have been increasingly used to induce and maintain disease remission in patients with Crohn’s disease (CD). Despite a considerable non-response rate, little is known about the…

Read More

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease.

Related Articles Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Apr 12;: Authors: Chaparro M, Garre A, Guerra Veloz MF, Vázquez JM, De Castro ML, Leo E, Rodriguez E, Carbajo AY, Riestra S, Jiménez I, Calvet X, Bujanda L, Rivero M, Gomollón F, Benítez JM, Bermejo F, Alcaide N, Gutiérrez A, Mañosa M, Iborra M, Lorente R, Rojas-Feria M, Barreiro-de Acosta M, Kolle L, Van Domselaar M, Amo V, Argüelles F, Ramírez E, Morell A, Bernardo D, Gisbert…

Read More

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study.

Related Articles Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019 Mar 28;: Authors: Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, Fishman S, Levchenko O, Cheon JH, Scribano ML, Mateescu RB, Lee KM, Eun CS, Lee SJ, Lee SY, Kim H, Schreiber S, Fowler H, Cheung R, Kim YH Abstract BACKGROUND: The infliximab biosimilar CT-P13 was approved for use in Crohn’s disease after clinical comparison with originator infliximab…

Read More

Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.

Related Articles Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Inflamm Bowel Dis. 2019 Apr 01;: Authors: Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC, Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Abstract BACKGROUND: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerative colitis (UC) patients who failed infliximab…

Read More
<< Go Back